<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758836</url>
  </required_header>
  <id_info>
    <org_study_id>0974-046</org_study_id>
    <secondary_id>2008_551</secondary_id>
    <secondary_id>CTRI/2009/091/000291</secondary_id>
    <nct_id>NCT00758836</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)</brief_title>
  <official_title>A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0974 Co-administered With Ibuprofen or Acetaminophen in Patients With Migraine With or Without Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and how effective telcagepant is when taken with ibuprofen or
      acetaminophen in participants with migraine with or without aura. The primary study
      hypothesis is that at least one drug combination is superior to telecagepant alone in the
      treatment of acute migraines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2008</start_date>
  <completion_date type="Actual">August 24, 2009</completion_date>
  <primary_completion_date type="Actual">August 24, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pain Freedom at Two Hours Post-dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain freedom was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to no pain (Grade 0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events Within 48 Hours Post-dose (Count ≥4 in One or More Treatment Groups)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events Within 14 Days Post-dose (Count ≥4 in One or More Treatment Groups)</measure>
    <time_frame>Up to 14 days post-dose</time_frame>
    <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Relief at 2 Hours Post-dose.</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain relief was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to mild or none (Grade 1 or 0).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">683</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telcagepant 280 mg +Ibuprofen 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telcagepant 280 mg +APAP 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telcagepant 280 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <arm_group_label>Telcagepant 280 mg +Ibuprofen 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetominophen</intervention_name>
    <arm_group_label>Telcagepant 280 mg +APAP 1000 mg</arm_group_label>
    <other_name>N-acetyl-p-aminophenol (APAP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telcagepant</intervention_name>
    <arm_group_label>Telcagepant 280 mg +Ibuprofen 400 mg</arm_group_label>
    <arm_group_label>Telcagepant 280 mg +APAP 1000 mg</arm_group_label>
    <arm_group_label>Telcagepant 280 mg</arm_group_label>
    <other_name>MK-0974</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years of age or older

          -  History of migraine with or without aura for more than 1 year with 1-8 moderate or
             severe migraine attacks per month in the 2 months prior to starting in the study

          -  Willing to stay awake for at least 2 hours after taking study drug

          -  Able to read, understand and complete questionnaires and diaries

        Exclusion Criteria:

          -  Breast-feeding, pregnant, or plan to become pregnant during the study

          -  Not able to tell migraine attack from other headaches

          -  Older than 50 years of age at migraine onset

          -  Have more than 15 headache days per month or have taken medication for acute headache
             on more than 10 days per month in any of the 3 months before starting in the study

          -  History of gastric or small intestinal surgery

          -  History of heart attack, stroke, unstable angina, coronary artery bypass surgery or
             transient ischemic attack in the 3 months before starting in the study

          -  Currently participating or have participated in a study with in investigational
             compound or device in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>July 18, 2014</results_first_submitted>
  <results_first_submitted_qc>July 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2014</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0974-046&amp;kw=0974-046&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="P2">
          <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="P3">
          <title>Telcagepant 280 mg +APAP 1000 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="P4">
          <title>Telcagepant 280 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="171"/>
                <participants group_id="P4" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="B2">
          <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="B3">
          <title>Telcagepant 280 mg +APAP 1000 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="B4">
          <title>Telcagepant 280 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="171"/>
            <count group_id="B4" value="170"/>
            <count group_id="B5" value="683"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="145"/>
                    <measurement group_id="B5" value="583"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pain Freedom at Two Hours Post-dose</title>
        <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain freedom was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to no pain (Grade 0).</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>The Full Analysis Set (FAS) comprised participants who were treated and had a baseline assessment and at least one post-dose assessment up to or including the 2-hour time point. Missing data were imputed by using a Last Observation Carried Forward (LOCF) approach; baseline values were not carried forward to impute the missing post-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O2">
            <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O3">
            <title>Telcagepant 280 mg +APAP 1000 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O4">
            <title>Telcagepant 280 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Freedom at Two Hours Post-dose</title>
          <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain freedom was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to no pain (Grade 0).</description>
          <population>The Full Analysis Set (FAS) comprised participants who were treated and had a baseline assessment and at least one post-dose assessment up to or including the 2-hour time point. Missing data were imputed by using a Last Observation Carried Forward (LOCF) approach; baseline values were not carried forward to impute the missing post-treatment data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="38.3"/>
                    <measurement group_id="O4" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomial distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>24.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.7</ci_lower_limit>
            <ci_upper_limit>32.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>27.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.6</ci_lower_limit>
            <ci_upper_limit>35.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>20.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.6</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion differenece</param_type>
            <param_value>4.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>7.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Relief at 2 Hours Post-dose.</title>
        <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain relief was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to mild or none (Grade 1 or 0).</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>The FAS comprised participants who were treated and had a baseline assessment and at least one post-dose assessment up to or including the 2-hour time point. Missing data were imputed by using a Last Observation Carried Forward (LOCF) approach; baseline values were not carried forward to impute the missing post-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O2">
            <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O3">
            <title>Telcagepant 280 mg +APAP 1000 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O4">
            <title>Telcagepant 280 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Relief at 2 Hours Post-dose.</title>
          <description>Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain relief was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to mild or none (Grade 1 or 0).</description>
          <population>The FAS comprised participants who were treated and had a baseline assessment and at least one post-dose assessment up to or including the 2-hour time point. Missing data were imputed by using a Last Observation Carried Forward (LOCF) approach; baseline values were not carried forward to impute the missing post-treatment data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="71.0"/>
                    <measurement group_id="O3" value="69.9"/>
                    <measurement group_id="O4" value="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>40.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.9</ci_lower_limit>
            <ci_upper_limit>49.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>39.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.5</ci_lower_limit>
            <ci_upper_limit>48.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>6.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for independent binomal distribution stratified by baseline severity.</method_desc>
            <param_type>Proportion difference</param_type>
            <param_value>34.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.3</ci_lower_limit>
            <ci_upper_limit>43.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events Within 48 Hours Post-dose (Count ≥4 in One or More Treatment Groups)</title>
        <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
        <time_frame>Up to 48 hours post-dose</time_frame>
        <population>All participants as treated (one participant assigned to the Telcagepant 280 mg arm only took the placebo tablet and is included in the Placebo arm for adverse event reporting).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O2">
            <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O3">
            <title>Telcagepant 280 mg +APAP 1000 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O4">
            <title>Telcagepant 280 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events Within 48 Hours Post-dose (Count ≥4 in One or More Treatment Groups)</title>
          <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
          <population>All participants as treated (one participant assigned to the Telcagepant 280 mg arm only took the placebo tablet and is included in the Placebo arm for adverse event reporting).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events Within 14 Days Post-dose (Count ≥4 in One or More Treatment Groups)</title>
        <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
        <time_frame>Up to 14 days post-dose</time_frame>
        <population>All participants as treated (one participant assigned to the Telcagepant 280 mg arm only took the placebo tablet and is included in the Placebo arm for adverse event reporting).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O2">
            <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O3">
            <title>Telcagepant 280 mg +APAP 1000 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
          </group>
          <group group_id="O4">
            <title>Telcagepant 280 mg</title>
            <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events Within 14 Days Post-dose (Count ≥4 in One or More Treatment Groups)</title>
          <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
          <population>All participants as treated (one participant assigned to the Telcagepant 280 mg arm only took the placebo tablet and is included in the Placebo arm for adverse event reporting).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after the dose was taken.</time_frame>
      <desc>One participant randomly assigned to the Telcagepant 280 mg arm took only the placebp tablet and is included in the Placebo arm for adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="E2">
          <title>Telcagepant 280 mg +Ibuprofen 400 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="E3">
          <title>Telcagepant 280 mg +APAP 1000 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine</description>
        </group>
        <group group_id="E4">
          <title>Telcagepant 280 mg</title>
          <description>Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

